Wafik S El-Deiry

List of Publications by Year
in descending order

407 papers	47,258 citations	3334 91 h-index	1934 207 g-index
551 all docs	551 docs citations	551 times ranked	57367 citing authors

#	Article	IF	Citations
1	Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells. Molecular Cancer Research, 2022, 20, 622-636.	3.4	13
2	Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. Cancers, 2022, 14, 1028.	3.7	24
3	BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 128-128.	1.6	2
4	Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2704-2714.	7.0	57
5	Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules, 2022, 12, 548.	4.0	21
6	Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles.. American Journal of Cancer Research, 2022, 12, 138-151.	1.4	0
7	miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.. American Journal of Cancer Research, 2022, 12, 315-326.	1.4	0
8	Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).. American Journal of Cancer Research, 2022, 12, 729-743.	1.4	0
9	Integrin/TGF-Î²1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. Pharmaceuticals, 2022, 15, 618.	3.8	12
10	Abstract 3709: Synergistic activity of ABT-263 and ONC201 against solid tumor cell lines is associated with suppression of BAG3, Mcl-1, pAkt, and upregulation of Noxa along with Bax cleavage during apoptosis. Cancer Research, 2022, 82, 3709-3709.	0.9	1
11	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3Î²) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Cancer Biology and Therapy, 2022, 23, 417-423.	3.4	7
12	First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, e43-e52.	2.3	5
13	The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer Therapeutics, 2021, 20, 183-190.	4.1	6
14	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget, 2021, 12, 2131-2146.	1.8	3
15	P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. Neoplasia, 2021, 23, 304-325.	5.3	15
16	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells, 2021, 10, 1275.	4.1	4
17	Strategies to sensitize cancer cells to immunotherapy. Human Vaccines and Immunotherapeutics, 2021, 17, 2595-2601.	3.3	9
18	The Role of BCL-2 Proteins in the Development of Castration-resistant Prostate Cancer and Emerging Therapeutic Strategies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 374-382.	1.3	4

#	Article	IF	Citations
19	ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1572-1583.	4.1	13
20	Abstract 1060: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death. , 2021, , .		1
21	A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. ELife, 2021, 10, .	6.0	11
22	Abstract 2195: Differential transcriptomic profiling of primary tumors and metastatic sites in advanced prostate cancer. , 2021, , .		0
23	Abstract 962: Small-molecule NSC58874 releases and activates p73 via induction of mutant p53 degradation in cancer cells. , 2021, , .		0
24	Abstract 635: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG). , 2021, , .		0
25	Abstract 1205: Clinical and genomic features of advanced urothelial carcinoma with 9p21 deletion. , 2021, , .		0
26	Abstract 1006: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines. Cancer Research, 2021, 81, 1006-1006.	0.9	2
27	Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188556.	7.4	181
28	Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies. Frontiers in Pharmacology, 2021, 12, 747180.	3.5	8
29	EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia, 2021, 23, 792-810.	5.3	26
30	A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs. Oncotarget, 2021, 12, 1980-1991.	1.8	7
31	Targeting the Integrated Stress Response in Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 747837.	3.5	80
32	Identification of Smurf2 as a HIF-1Î± degrading E3 ubiquitin ligase. Oncotarget, 2021, 12, 1970-1979.	1.8	5
33	Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients. Oncotarget, 2021, 12, 1992-2005.	1.8	7
34	Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. Journal of Molecular Diagnostics, 2021, 23, 1761-1773.	2.8	2
35	Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells. Oncotarget, 2021, 12, 2006-2021.	1.8	8
36	Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2. ELife, 2021, 10, .	6.0	21

#	Article	IF	Citations
37	Molecular characterization of squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology, 2021, 12, 2423-2437.	1.4	7
38	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
39	Anti-cancer efficacy includingÂRb-deficient tumorsÂandÂVHL-independent HIF1Î±Âproteasomal destabilizationÂby dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports, 2021, 11, 20871.	3.3	9
40	Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents. International Journal of Molecular Sciences, 2021, 22, 11828.	4.1	19
41	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. Cancer Biology and Therapy, 2021, , 1-10.	3.4	6
42	Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 68-73.	1.3	5
43	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Frontiers in Pharmacology, 2021, 12, 747194.	3.5	14
44	Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. American Journal of Cancer Research, 2021, 11, 4607-4623.	1.4	2
45	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 751568.	3.5	10
46	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Cancer Biology and Therapy, 2021, 22, 607-618.	3.4	10
47	Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors. Frontiers in Pharmacology, 2021, 12, 747895.	3.5	10
48	CDKN1A/p21, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. American Journal of Cancer Research, 2021, 11, 5452-5471.	1.4	2
49	Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.. American Journal of Cancer Research, 2021, 11, 6086-6106.	1.4	1
50	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery, 2020, 6, 57.	4.7	41
51	Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. Frontiers in Immunology, 2020, 11, 595289.	4.8	3
52	ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia, 2020, 22, 725-744.	5.3	90
53	Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3KÎ³ isoform. Communications Biology, 2020, 3, 267.	4.4	21
54	Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology, 2020, 17, 395-417.	27.6	1,192

#	Article	IF	Citations
55	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget, 2020, 11, 3753-3769.	1.8	18
56	MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. Oncotarget, 2020, 11, 4201-4223.	1.8	22
57	DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, iii299-iii299.	1.2	1
58	Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer Biology and Therapy, 2019, 20, 1389-1397.	3.4	6
59	Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. Oncologist, 2019, 24, 1416-1419.	3.7	32
60	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. , 2019, 7, 136.		48
61	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	329.8	203
62	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia, 2019, 33, 2429-2441.	7.2	24
63	Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). Frontiers in Oncology, 2019, 9, 142.	2.8	6
64	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research, 2019, 25, 2305-2313.	7.0	43
65	A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15020-e15020.	1.6	0
66	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
67	Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia, 2018, 20, 244-255.	5.3	18
68	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
69	Bcl-2 Protein Targeting by the p53/p21 Complexâ€”Letter. Cancer Research, 2018, 78, 2770-2771.	0.9	5
70	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research, 2018, 16, 754-766.	3.4	21
71	CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell Cycle, 2018, 17, 557-567.	2.6	10
72	Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia, 2018, 20, 80-91.	5.3	96

#	Article	IF	Citations
73	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle, 2018, 17, 468-478.	2.6	34
74	Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. Journal of Experimental and Clinical Cancer Research, 2018, 37, 11.	8.6	37
75	TRAIL pathway targeting therapeutics. Expert Review of Precision Medicine and Drug Development, 2018, 3, 197-204.	0.7	24
76	Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Frontiers in Oncology, 2018, 8, 652.	2.8	14
77	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 2018, 128, 2325-2338.	8.2	52
78	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	1.6	318
79	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.9	68
80	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Nonâ€“Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Molecular Cancer Therapeutics, 2017, 16, 1290-1298.	4.1	40
81	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle, 2017, 16, 1790-1799.	2.6	53
82	Impact of perineural invasion on survival in node negative colon cancer. Cancer Biology and Therapy, 2017, 18, 740-745.	3.4	17
83	Tissue TGF-Î² expression following conventional radiotherapy and pulsed low-dose-rate radiation. Cell Cycle, 2017, 16, 1171-1174.	2.6	20
84	The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle, 2017, 16, 1193-1200.	2.6	39
85	First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2017, 23, 4163-4169.	7.0	119
86	miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research, 2017, 77, 6902-6913.	0.9	43
87	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology and Therapy, 2017, 18, 694-704.	3.4	13
88	P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Scientific Reports, 2017, 7, 9711.	3.3	24
89	Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. Cancer Biology and Therapy, 2017, 18, 651-654.	3.4	7
90	Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth. Cell Cycle, 2017, 16, 1719-1725.	2.6	7

#	Article	IF	Citations
91	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
92	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget, 2017, 8, 29887-29905.	1.8	9
93	BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget, 2017, 8, 39945-39962.	1.8	29
94	MMR-deficiency and BRCA2/EGFR/NTRK mutations. Aging, 2017, 9, 1849-1850.	3.1	1
95	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	1.8	147
96	Circulating tumor cells: silent predictors of metastasis. F1000Research, 2017, 6, 1445.	1.6	37
97	Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget, 2017, 8, 66747-66757.	1.8	92
98	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, e8-e15.	3.8	13
99	Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-25.	0.1	1
100	Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway. Cancer Research, 2017, 77, 2792-2792.	0.9	3
101	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE, 2017, 12, e0180541.	2.5	28
102	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget, 2017, 8, 81776-81793.	1.8	34
103	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Translational Cancer Research, 2017, 6, S1239-S1243.	1.0	31
104	The tuberous sclerosis complex gets fatter. Oncotarget, 2017, 8, 41780-41781.	1.8	1
105	A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget, 2016, 7, 3662-3676.	1.8	27
106	Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports, 2016, 12, 151-161.	0.5	55
107	p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy. Cancer Research, 2016, 76, 5189-5191.	0.9	197
108	Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). Clinical Cancer Research, 2016, 22, 6192-6203.	7.0	35

#	Article	IF	Citations
109	The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. Journal of Biological Chemistry, 2016, 291, 5960-5970.	3.4	20
110	Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated Î”Np73 Inhibition and p73 Activation. Cancer Research, 2016, 76, 1989-1999.	0.9	53
111	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
112	ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2Î± kinases. Science Signaling, 2016, 9, ra18.	3.6	145
113	Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity. Cancer Research, 2016, 76, 700-712.	0.9	14
114	Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget, 2016, 7, 74380-74392.	1.8	111
115	Are we ready to assess the value of treatment options in oncology?. Cancer Biology and Therapy, 2015, 16, 1427-1429.	3.4	0
116	Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion on Therapeutic Targets, 2015, 19, 1171-1185.	3.4	86
117	ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle, 2015, 14, 2422-2428.	2.6	28
118	Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer, 2015, 14, 99.	19.2	70
119	Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research, 2015, 75, 1668-1674.	0.9	40
120	Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology and Therapy, 2015, 16, 1710-1719.	3.4	15
121	TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. Journal of Hepatology, 2015, 62, 1156-1163.	3.7	85
122	A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Molecular Cancer Therapeutics, 2015, 14, 835-843.	4.1	15
123	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stemâ€“like Cells in an Akt/Foxo3a/TRAILâ€“Dependent Manner. Cancer Research, 2015, 75, 1423-1432.	0.9	113
124	Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biology and Therapy, 2015, 16, 1136-1139.	3.4	0
125	Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biology and Therapy, 2015, 16, 709-713.	3.4	24
126	Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biology and Therapy, 2015, 16, 699-708.	3.4	55

#	Article	IF	Citations
127	Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biology and Therapy, 2015, 16, 690-698.	3.4	26
128	Acoustic separation of circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4970-4975.	7.1	632
129	A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. Cancer Biology and Therapy, 2015, 16, 377-382.	3.4	4
130	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Research, 2015, 75, 3842-3852.	0.9	89
131	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biology and Therapy, 2015, 16, 1726-1737.	3.4	75
132	Therapeutic biomarker differences between MSI-H and MSS colorectal cancers.. Journal of Clinical Oncology, 2015, 33, 3597-3597.	1.6	2
133	Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite instable (MSI-H) colorectal cancer (CRC) and association of wnt pathway corepressor TLE-3.. Journal of Clinical Oncology, 2015, 33, 3611-3611.	1.6	3
134	First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS ONE, 2015, 10, e0143082.	2.5	41
135	Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. Oncotarget, 2015, 6, 3784-3796.	1.8	19
136	Novel and Emerging Targeted Therapies of Colorectal Cancer. Current Clinical Pharmacology, 2015, 10, 279-298.	0.6	6
137	Association of increase in BRCA2 gene mutations in microsatellite instable (MSI-H) colorectal ancer (CRC) with increased c-MET expression.. Journal of Clinical Oncology, 2015, 33, e14684-e14684.	1.6	0
138	Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis. , 2015, , .		1
139	The NFÎºB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biology and Therapy, 2014, 15, 602-611.	3.4	18
140	Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology and Therapy, 2014, 15, 443-451.	3.4	20
141	Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. Oncology Letters, 2014, 7, 2110-2112.	1.8	2
142	Prodigiosin Rescues Deficient p53 Signaling and Antitumor Effects via Upregulating p73 and Disrupting Its Interaction with Mutant p53. Cancer Research, 2014, 74, 1153-1165.	0.9	70
143	COX-2 Drives Metastatic Breast Cells from Brain Lesions into the Cerebrospinal Fluid and Systemic Circulation. Cancer Research, 2014, 74, 2385-2390.	0.9	16
144	Flexible Micro Spring Array Device for High-Throughput Enrichment of Viable Circulating Tumor Cells. Clinical Chemistry, 2014, 60, 323-333.	3.2	119

#	Article	IF	Citations
145	Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5â€“Fluorouracil-Based Chemotherapy Regimens. Clinical Colorectal Cancer, 2014, 13, 119-126.	2.3	34
146	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-Râ€“mediated apoptosis. Journal of Clinical Investigation, 2014, 124, 2626-2639.	8.2	286
147	ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood, 2014, 124, 5219-5219.	1.4	2
148	Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget, 2014, 5, 1753-1760.	1.8	26
149	The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget, 2014, 5, 12728-12737.	1.8	37
150	HIF-1 Signaling in Drug Resistance to Chemotherapy. Current Medicinal Chemistry, 2014, 21, 3021-3028.	2.4	93
151	Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities. Current Drug Targets, 2014, 15, 80-89.	2.1	209
152	Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells. Blood, 2014, 124, 5233-5233.	1.4	0
153	Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins. Blood, 2014, 124, 5237-5237.	1.4	1
154	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	1.6	1
155	Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects. Science Translational Medicine, 2013, 5, 171ra17.	12.4	252
156	Novel Antineoplastics Targeting Genetic Changes in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 1-34.	1.6	7
157	Investing in biomedical research is important. Cancer Biology and Therapy, 2013, 14, 869-870.	3.4	0
158	CDK1 stabilizes HIF-1Î± via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle, 2013, 12, 3689-3701.	2.6	84
159	Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle, 2013, 12, 2132-2143.	2.6	23
160	Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals, 2013, 6, 988-1038.	3.8	16
161	Detection of DSS-induced gastrointestinal mucositis in mice by non-invasive optical near-infrared (NIR) imaging of cathepsin activity. Cancer Biology and Therapy, 2013, 14, 736-741.	3.4	6
162	p21WAF1 and tumourigenesis. Current Opinion in Oncology, 2013, 25, 52-58.	2.4	255

#	Article	IF	Citations
163	Contradictory KRAS mutation test results in a patient with metastatic colon cancer. Cancer Biology and Therapy, 2013, 14, 699-702.	3.4	4
164	Welcoming Paul Dent as Assistant Editor-in-Chief ofCancer Biology & Therapy. Cancer Biology and Therapy, 2013, 14, 773-773.	3.4	0
165	Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients. Cancer Biology and Therapy, 2013, 14, 1174-1181.	3.4	14
166	The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo. Cell Cycle, 2013, 12, 2241-2247.	2.6	5
167	FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biology and Therapy, 2013, 14, 711-719.	3.4	11
168	REDOX IMAGING OF THE p53-DEPENDENT MITOCHONDRIAL REDOX STATE IN COLON CANCEREX VIVO. Journal of Innovative Optical Health Sciences, 2013, 06, 1350016.	1.0	15
169	Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biology and Therapy, 2013, 14, 703-710.	3.4	30
170	Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis. PLoS ONE, 2013, 8, e75414.	2.5	43
171	The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer. PLoS ONE, 2013, 8, e59380.	2.5	12
172	Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on Î²-catenin. Oncotarget, 2013, 4, 184-191.	1.8	7
173	CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle, 2012, 11, 2592-2593.	2.6	5
174	Inefficient boosting of antitumor CD8+T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. OncoImmunology, 2012, 1, 1507-1516.	4.6	6
175	Regulation of the human TRAIL gene. Cancer Biology and Therapy, 2012, 13, 1143-1151.	3.4	79
176	An integrated, multiparametric flow cytometry chip using â€œmicrofluidic driftingâ€•based three-dimensional hydrodynamic focusing. Biomicrofluidics, 2012, 6, 24113-241139.	2.4	102
177	Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9. Molecular Cancer Therapeutics, 2012, 11, 2321-2330.	4.1	12
178	Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes. Molecular Cancer Therapeutics, 2012, 11, 2087-2095.	4.1	24
179	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
180	Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opinion on Therapeutic Targets, 2012, 16, 1161-1174.	3.4	38

#	Article	IF	Citations
181	Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors. Cell Cycle, 2012, 11, 3312-3323.	2.6	27
182	Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncology Reports, 2012, 28, 883-888.	2.6	1
183	Abstract 3625: A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary (CUP) using circulating tumor cells. , 2012, , .		1
184	Compartmentalization of tumor cells to the CSF or peripheral blood of a breast cancer patient with CNS metastasis.. Journal of Clinical Oncology, 2012, 30, e11544-e11544.	1.6	0
185	Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3Î² and CDK1. Cancer Research, 2011, 71, 5265-5275.	0.9	29
186	Utility of Dual-modality Bioluminescence and MRI in Monitoring Stem Cell Survival and Impact on Post Myocardial Infarct Remodeling. Academic Radiology, 2011, 18, 3-12.	2.5	18
187	Oxaliplatin Uses JNK to Restore TRAIL Sensitivity in Cancer Cells Through Bcl-xL Inactivation. Gastroenterology, 2011, 141, 430-434.	1.3	9
188	High-Resolution Imaging and Antitumor Effects of GFP+ Bone Marrow-Derived Cells Homing to Syngeneic Mouse Colon Tumors. American Journal of Pathology, 2011, 179, 2169-2176.	3.8	3
189	Death Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis. Journal of Biological Chemistry, 2011, 286, 39336-39348.	3.4	106
190	Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget, 2011, 2, 752-760.	1.8	81
191	The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle, 2011, 10, 2380-2389.	2.6	59
192	FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. International Journal of Oncology, 2011, 39, 91-100.	3.3	3
193	Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biology and Therapy, 2011, 12, 335-348.	3.4	10
194	Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation. Science Translational Medicine, 2011, 3, 86ra50.	12.4	40
195	Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biology and Therapy, 2011, 12, 239-251.	3.4	40
196	Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biology and Therapy, 2011, 12, 349-356.	3.4	15
197	Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biology and Therapy, 2011, 12, 229-238.	3.4	47
198	Hyperspectral imaging: A non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biology and Therapy, 2011, 12, 326-334.	3.4	5

#	Article	IF	Citations
199	Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biology and Therapy, 2011, 12, 557-568.	3.4	18
200	Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle, 2011, 10, 2331-2338.	2.6	54
201	Abstract 5248: Quantum dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells. , 2011, , .		2
202	Funding the marathon: Investigators need more than basic experiments and clinical trials to advance the war on cancer. Cancer Biology and Therapy, 2010, 9, 751-753.	3.4	0
203	Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports, 2010, 6, 212-220.	0.5	54
204	Current strategies to target p53 in cancer. Biochemical Pharmacology, 2010, 80, 724-730.	4.4	144
205	The Mycâ€“miR-17â^¼92 Axis Blunts TGFÎ² Signaling and Production of Multiple TGFÎ²-Dependent Antiangiogenic Factors. Cancer Research, 2010, 70, 8233-8246.	0.9	248
206	TRAIL receptor signaling and therapeutics. Expert Opinion on Therapeutic Targets, 2010, 14, 1091-1108.	3.4	144
207	Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology and Therapy, 2009, 8, 2193-2204.	3.4	15
208	Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biology and Therapy, 2009, 8, 2406-2416.	3.4	25
209	The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biology and Therapy, 2009, 8, 2185-2192.	3.4	27
210	The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions. Cell Cycle, 2009, 8, 4168-4175.	2.6	72
211	Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biology and Therapy, 2009, 8, 2417-2444.	3.4	14
212	Tumor necrosis factorâ€“related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Molecular Cancer Therapeutics, 2009, 8, 3285-3295.	4.1	33
213	Multispectral Fluorescence Imaging. Journal of Nuclear Medicine, 2009, 50, 1563-1566.	5.0	54
214	Response: CARP1 regulates induction of NF-ÎºB by TNFÎ±. Current Biology, 2009, 19, R17-R19.	3.9	13
215	Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 597-606.	4.9	116
216	Cell Death: A New Par-4 the TRAIL. Cell, 2009, 138, 220-222.	28.9	9

#	Article	IF	Citations
217	Protective Effects of Dietary Antioxidants on Proton Total-Body Irradiation-Mediated Hematopoietic Cell and Animal Survival. Radiation Research, 2009, 172, 175-186.	1.5	47
218	ERK and MDM2 prey on FOXO3a. Nature Cell Biology, 2008, 10, 125-126.	10.3	45
219	CARP-2 Is an Endosome-Associated Ubiquitin Ligase for RIP and Regulates TNF-Induced NF-Î²B Activation. Current Biology, 2008, 18, 641-649.	3.9	65
220	The Essential Role of Fibroblasts in Esophageal Squamous Cell Carcinomaâ€“Induced Angiogenesis. Gastroenterology, 2008, 134, 1981-1993.	1.3	118
221	Invincible, but Not Invisible: Imaging Approaches Toward In Vivo Detection of Cancer Stem Cells. Journal of Clinical Oncology, 2008, 26, 2901-2910.	1.6	64
222	Regulation of Programmed Cell Death by the P53 Pathway. Advances in Experimental Medicine and Biology, 2008, 615, 201-221.	1.6	73
223	Mcl-1: A Gateway to TRAIL Sensitization. Cancer Research, 2008, 68, 2062-2064.	0.9	102
224	Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. Cancer Biology and Therapy, 2008, 7, 2023-2033.	3.4	60
225	Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biology and Therapy, 2008, 7, 2047-2053.	3.4	24
226	TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle, 2008, 7, 1525-1528.	2.6	37
227	Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biology and Therapy, 2008, 7, 2039-2046.	3.4	32
228	CARPs enhance p53 turnover by degrading 14-3-3σ and stabilizing MDM2. Cell Cycle, 2008, 7, 670-682.	2.6	35
229	TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells. Cancer Research, 2008, 68, 3440-3449.	0.9	43
230	Chapter 9 Studying p53â€Ðependent Cell Death In Vitro and In Vivo. Methods in Enzymology, 2008, 446, 159-173.	1.0	5
231	DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines. Cancer Research, 2008, 68, 909-917.	0.9	42
232	Structural and Functional Basis for Therapeutic Modulation of p53 Signaling. Clinical Cancer Research, 2008, 14, 6376-6386.	7.0	54
233	TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biology and Therapy, 2008, 7, 2034-2038.	3.4	88
234	Restoration of p53 to limit tumor growth. Current Opinion in Oncology, 2008, 20, 90-96.	2.4	96

#	Article	IF	Citations
235	Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing. BioTechniques, 2008, 45, 459-464.	1.8	34
236	TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. Journal of Clinical Investigation, 2008, 118, 111-123.	8.2	152
237	Cell Cycleâ€"Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation. Cancer Research, 2007, 67, 9443-9454.	0.9	125
238	CARPs Are Ubiquitin Ligases That Promote MDM2-independent p53 and Phospho-p53ser20 Degradation. Journal of Biological Chemistry, 2007, 282, 3273-3281.	3.4	74
239	P53, Cell Cycle Arrest and Apoptosis. , 2007, , 141-163.		7
240	Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the Non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biology and Therapy, 2007, 6, 1486-1491.	3.4	68
241	Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biology and Therapy, 2007, 6, 1649-1653.	3.4	13
242	Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biology and Therapy, 2007, 6, 1858-1866.	3.4	28
243	Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: Implications for monitoring angiogenesis. Cancer Biology and Therapy, 2007, 6, 447-453.	3.4	6
244	Replication Stress, Defective S-phase Checkpoint and Increased Death in Plk2-Deficient Human Cancer Cells. Cell Cycle, 2007, 6, 2571-2578.	2.6	55
245	CARPs are E3 ligases that target apical caspases and p53. Cancer Biology and Therapy, 2007, 6, 1676-1683.	3.4	13
246	IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biology and Therapy, 2007, 6, 534-540.	3.4	24
247	Hyperspectral Image Analysis of Live Cells in Various Cell Cycle Stages. Cell Cycle, 2007, 6, 2563-2570.	2.6	14
248	Effects of Low Confluency, Serum Starvation and Hypoxia on the Side Population of Cancer Cell Lines. Cell Cycle, 2007, 6, 2554-2562.	2.6	75
249	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes and Development, 2007, 21, 2788-2803.	5.9	156
250	Childhood ALL and second neoplasms. Cancer Biology and Therapy, 2007, 6, 1525-1531.	3.4	5
251	Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells. American Journal of Pathology, 2007, 170, 709-721.	3.8	123
252	p53, BRCA1 and Breast Cancer Chemoresistance. Advances in Experimental Medicine and Biology, 2007, 608, 70-86.	1.6	34

#	Article	IF	Citations
253	Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death. Cancer Cell, 2007, 12, 66-80.	16.8	241
254	The Extrinsic Pathway of Apoptosis. , 2007, , 31-54.		7
255	Targeting mutant p53 shows promise for sunscreens and skin cancer. Journal of Clinical Investigation, 2007, 117, 3658-3660.	8.2	13
256	p53, Cell Cycle Arrest and Apoptosis. , 2007, , 141-163.		0
257	The Complementary Roles of the Extrinsic and Intrinsic Apoptotic Pathways in Promoting the Death of Cancer Cells. Cancer Journal (Sudbury, Mass), 2006, 12, 247-249.	2.0	3
258	Critical role for Daxx in regulating Mdm2. Nature Cell Biology, 2006, 8, 855-862.	10.3	236
259	Taming NEMO to slay cancer cells. Cancer Biology and Therapy, 2006, 5, 1096-1097.	3.4	3
260	Insulin-like growth factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biology and Therapy, 2006, 5, 1408-1414.	3.4	38
261	Lobbying congress to make cancer funding a priority: What scientists can do. Cancer Biology and Therapy, 2006, 5, 467-469.	3.4	1
262	Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biology and Therapy, 2006, 5, 1228-1235.	3.4	28
263	What are caspases 3 and 7 doing upstream of the mitochondria?. Cancer Biology and Therapy, 2006, 5, 763-765.	3.4	117
264	EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American Journal of Physiology - Renal Physiology, 2006, 290, G404-G416.	3.4	29
265	p73 or p53 Directly Regulates Human p53 Transcription to Maintain Cell Cycle Checkpoints. Cancer Research, 2006, 66, 6982-6989.	0.9	100
266	Distinct Signaling Pathways in TRAIL- versus Tumor Necrosis Factor-Induced Apoptosis. Molecular and Cellular Biology, 2006, 26, 8136-8148.	2.3	124
267	Imaging and Oncologic Drug Development. Journal of Clinical Oncology, 2006, 24, 3261-3273.	1.6	82
268	Selective TRAIL-Induced Apoptosis in Dysplastic Neoplasia of the Colon May Lead to New Neoadjuvant or Adjuvant Therapies. Clinical Cancer Research, 2006, 12, 4132-4136.	7.0	12
269	Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biology and Therapy, 2006, 5, 1033-1038.	3.4	98
270	Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11003-11008.	7.1	126

#	Article	IF	Citations
271	Tumorigenic Conversion of Primary Human Esophageal Epithelial Cells Using Oncogene Combinations in the Absence of Exogenous Ras. Cancer Research, 2006, 66, 10415-10424.	0.9	38
272	Mammalian Cell Death Pathways. , 2005, , 1-41.		1
273	Phosphorylation of p21 in G 2 /M Promotes Cyclin B-Cdc2 Kinase Activity. Molecular and Cellular Biology, 2005, 25, 3364-3387.	2.3	114
274	p53-Dependent and p53-Independent Induction of Insulin-Like Growth Factor Binding Protein-3 by Deoxyribonucleic Acid Damage and Hypoxia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3568-3574.	3.6	57
275	Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biology and Therapy, 2005, 4, 885-892.	3.4	53
276	Acridine derivatives activate p53 and induce tumor cell death through bax. Cancer Biology and Therapy, 2005, 4, 893-898.	3.4	74
277	Overview of cell death signaling pathways. Cancer Biology and Therapy, 2005, 4, 147-171.	3.4	1,047
278	Glucocorticoid-induced Tumor Necrosis Factor Receptor Is a p21 Transcriptional Target Conferring Resistance of Keratinocytes to UV Light-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 37725-37731.	3.4	29
279	DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis. Molecular and Cellular Biology, 2005, 25, 2000-2013.	2.3	113
280	Plagiarism is not acceptable in science or forCancer Biology & Therapy. Cancer Biology and Therapy, 2005, 4, 619-620.	3.4	1
281	Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biology and Therapy, 2005, 4, 1014-1017.	3.4	19
282	Mxi1 is induced by hypoxia in a HIF-1â€“dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biology and Therapy, 2005, 4, 1285-1294.	3.4	104
283	Noninvasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-fluorouracil, CPT-11 and/or TRAIL. Cancer Biology and Therapy, 2005, 4, 937-942.	3.4	10
284	Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology and Therapy, 2005, 4, 1068-1074.	3.4	17
285	Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biology and Therapy, 2005, 4, 1409-1414.	3.4	24
286	Transcriptional Activation by p53: Mechanisms and Targeted Genes. , 2005, , 53-80.		1
287	Zebrafish: Swimming Towards a Role for Fanconi Genes in DNA Repair. Cancer Biology and Therapy, 2004, 3, 501-502.	3.4	11
288	Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6170-6175.	7.1	110

#	Article	IF	Citations
289	Myc-Transformed Epithelial Cells Down-Regulate Clusterin, Which Inhibits Their Growth in Vitro and Carcinogenesis in Vivo. Cancer Research, 2004, 64, 3126-3136.	0.9	68
290	Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-Fluorouracil. Cancer Research, 2004, 64, 6666-6672.	0.9	109
291	Epidermal Growth Factor Receptor Regulates Aberrant Expression of Insulin-Like Growth Factor-Binding Protein 3. Cancer Research, 2004, 64, 7711-7723.	0.9	84
292	Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity. Molecular and Cellular Biology, 2004, 24, 8541-8555.	2.3	227
293	Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells. Journal of Biological Chemistry, 2004, 279, 40044-40052.	3.4	77
294	Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype?. Cancer Biology and Therapy, 2004, 3, 614-616.	3.4	55
295	Cytochrome c: A Crosslink between the Mitochondria and the Endoplasmic Reticulum in Calcium-Dependent Apoptosis. Cancer Biology and Therapy, 2004, 3, 44-46.	3.4	17
296	P53-dependent induction of serine proteases in irradiated mouse colon. Cancer Biology and Therapy, 2004, 3, 1290-1297.	3.4	6
297	Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis. Journal of Biological Chemistry, 2004, 279, 35829-35839.	3.4	203
298	Crystal Structure of a FYVE-Type Zinc Finger Domain from the Caspase Regulator CARP2. Structure, 2004, 12, 2257-2263.	3.3	15
299	Targeting p53 by PTD-mediated transduction. Trends in Biotechnology, 2004, 22, 431-434.	9.3	19
300	Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell, 2004, 6, 597-609.	16.8	197
301	Targeting FOXO Kills Two Birds with One Stone. Chemistry and Biology, 2004, 11, 16-18.	6.0	10
302	Cell Cycle Checkpoint Control Mechanisms That Can Be Disrupted in Cancer. , 2004, 280, 099-162.		45
303	In vivo imaging of mlc2v-luciferase, a cardiac-specific reporter gene expression in mice1. Academic Radiology, 2004, 11, 1022-1028.	2.5	15
304	P53-dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biology and Therapy, 2004, 3, 871-875.	3.4	22
305	Apoptosis Signaling in Normal and Cancer Cells. , 2004, , 497-521.		1
306	The P53 Pathway: Targets for the Development of Novel Cancer Therapeutics. , 2004, 119, 175-181.		27

#	Article	IF	Citations
307	Clinical Implication of p53 Mutation in Lung Cancer. Molecular Biotechnology, 2003, 24, 141-156.	2.4	57
308	Cell surface Death Receptor signaling in normal and cancer cells. Seminars in Cancer Biology, 2003, 13, 135-147.	9.6	270
309	Stroma Formation and Angiogenesis by Overexpression of Growth Factors, Cytokines, and Proteolytic Enzymes in Human Skin Grafted to SCID Mice. Journal of Investigative Dermatology, 2003, 120, 683-692.	0.7	44
310	P53 and radiation responses. Oncogene, 2003, 22, 5774-5783.	5.9	444
311	Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73Î². Oncogene, 2003, 22, 8394-8402.	5.9	30
312	The role of p53 in chemosensitivity and radiosensitivity. Oncogene, 2003, 22, 7486-7495.	5.9	288
313	TRAIL and apoptosis induction by TNF-family death receptors. Oncogene, 2003, 22, 8628-8633.	5.9	796
314	Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippelâ€“Lindau protein. Nature Genetics, 2003, 35, 229-237.	21.4	73
315	DNA Footprinting. , 2003, 223, 117-128.		1
316	Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding. Molecular and Cellular Biology, 2003, 23, 2171-2181.	2.3	147
317	Identification and Characterization of the Cytoplasmic Protein TRAF4 as a p53-regulated Proapoptotic Gene. Journal of Biological Chemistry, 2003, 278, 36435-36444.	3.4	59
318	Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis, 2003, 24, 47-51.	2.8	91
319	Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells. Molecular and Cellular Biology, 2003, 23, 5556-5571.	2.3	211
320	Regulation of the p53 Homolog p73 by Adenoviral Oncogene E1A. Journal of Biological Chemistry, 2003, 278, 18313-18320.	3.4	24
321	Restoring p53-Dependent Tumor Suppression. Cancer Biology and Therapy, 2003, 2, 54-62.	3.4	35
322	Bioluminescent Molecular Imaging of Endogenous and Exogenous p53-Mediated Transcription In Vitro and In Vivo Using an HCT116 Human Colon Carcinoma Xenograft Model. Cancer Biology and Therapy, 2003, 2, 196-202.	3.4	81
323	BRCA1 Augments Transcription by the NF-Î°B Transcription Factor by Binding to the Rel Domain of the p65/RelA Subunit. Journal of Biological Chemistry, 2003, 278, 26333-26341.	3.4	67
324	Caspase 10 Levels are Increased Following DNA Damage in a p53-Dependent Manner. Cancer Biology and Therapy, 2003, 2, 705-710.	3.4	30

#	Article	IF	Citations
325	Microarray Expression Profiling of p53-Dependent Transcriptional Changes in an Immortalized Mouse Embryo Fibroblast Cell Line. Cancer Biology and Therapy, 2003, 2, 416-430.	3.4	15
326	Microarray Analysis of p53 Target Gene Expression Patterns in the Spleen and Thymus in Response to Ionizing Radiation. Cancer Biology and Therapy, 2003, 2, 431-443.	3.4	59
327	Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15095-15100.	7.1	145
328	Identification of DNA-Binding of Tumor Suppressor Genes by Chromatin Immunoprecipitation. , 2003, 223, 129-134.		5
329	Cell Death Signaling in Malignancy. , 2003, 115, 319-343.		11
330	Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Research, 2003, 63, 5299-307.	0.9	42
331	Restoring p53-dependent tumor suppression. Cancer Biology and Therapy, 2003, 2, S55-63.	3.4	37
332	Transactivation of Repair Genes by BRCA1. Cancer Biology and Therapy, 2002, 1, 490-491.	3.4	53
333	Cancer Gene Therapy with the p53 Tumor Suppressor Gene. , 2002, , 299-313.		1
334	Cancer Gene Therapy with Tumor Suppressor Genes Involved in Cell-Cycle Control. , 2002, , 279-297.		0
335	Structure-based Design of p18INK4cProteins with Increased Thermodynamic Stability and Cell Cycle Inhibitory Activity. Journal of Biological Chemistry, 2002, 277, 48827-48833.	3.4	13
336	Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9492-9497.	7.1	158
337	BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets. Molecular and Cellular Biology, 2002, 22, 4280-4292.	2.3	145
338	IGFBP-3 mediates p53-induced apoptosis during serum starvation. International Journal of Oncology, 2002, 21, 327.	3.3	27
339	Enhanced Sensitivity of G1 Arrested Human Cancer Cells Suggests a Novel Therapeutic Strategy Using a Combination of Simvastatin and TRAIL. Cell Cycle, 2002, 1, 79-86.	2.6	70
340	Phenomenology and Scientific Progress. Cancer Biology and Therapy, 2002, 1, 436-437.	3.4	45
341	BRCA1 Transcriptionally Regulates Damaged DNA Binding Protein (DDB2) In the DNA Repair Response Following UV-Irradiation. Cancer Biology and Therapy, 2002, 1, 177-186.	3.4	84
342	Clinical and Molecular Features of Small cell Lung Cancer. Cancer Biology and Therapy, 2002, 1, 105-112.	3.4	7

#	Article	IF	Citations
343	Killer/DR5, A Novel DNA-Damage Inducible Death Receptor Gene, Links the p53-Tumor Suppressor to Caspase Activation and Apoptotic Death. Advances in Experimental Medicine and Biology, 2002, 465, 143-151.	1.6	62
344	Heat Shock Protects HCT116 and H460 Cells from TRAIL-Induced Apoptosis. Experimental Cell Research, 2002, 281, 175-181.	2.6	24
345	Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL. Neoplasia, 2002, 4, 551-557.	5.3	194
346	The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis. Cancer Biology and Therapy, 2002, 1, 47-55.	3.4	127
347	Derangement of growth and differentiation control in oncogenesis. BioEssays, 2002, 24, 83-90.	2.5	27
348	Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene, 2002, 21, 2623-2633.	5.9	93
349	BID regulation by p53 contributes to chemosensitivity. Nature Cell Biology, 2002, 4, 842-849.	10.3	370
350	p53 and Its Targets. , 2002, , 77-96.		0
351	IGFBP-3 mediates p53-induced apoptosis during serum starvation. International Journal of Oncology, 2002, 21, 327-35.	3.3	19
352	Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 2002, 1, 82-9.	2.6	43
353	The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle, 2002, 1, 90-6.	2.6	13
354	Tissue-specific induction of p53 targets in vivo. Cancer Research, 2002, 62, 7316-27.	0.9	185
355	p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-Î³. Experimental Cell Research, 2001, 262, 154-169.	2.6	136
356	Growth inhibitory effect of p21 and p53 containing adenoviruses on transitional cell carcinoma cell lines in vitro and in vivo. Urologic Oncology: Seminars and Original Investigations, 2001, 6, 155-162.	1.6	6
357	Checkpoint genes in cancer. Annals of Medicine, 2001, 33, 113-122.	3.8	57
358	Optical imaging. , 2001, , 172-182.		0
359	Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene, 2001, 20, 4601-4612.	5.9	132
360	Akt takes centre stage in cell-cycle deregulation. Nature Cell Biology, 2001, 3, E71-E73.	10.3	45

#	Article	IF	Citations
361	The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis. Journal of Biological Chemistry, 2001, 276, 38610-38618.	3.4	162
362	Pioglitazone Inhibits Growth of Carcinoid Cells and Promotes TRAIL-Induced Apoptosis by Induction of p21^{waf1/cip1}. Digestion, 2001, 64, 75-80.	2.3	57
363	Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive Colon Carcinoma Cell Line SW480 Using a Genetic Approach. Journal of Biological Chemistry, 2001, 276, 37879-37886.	3.4	146
364	Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. International Journal of Oncology, 2001, 18, 241-7.	3.3	17
365	Death Domain Mutagenesis of KILLER/DR5 Reveals Residues Critical for Apoptotic Signaling. Journal of Biological Chemistry, 2001, 276, 14939-14945.	3.4	45
366	Pointing (zinc) fingers at BRCA1 targets. Nature Medicine, 2000, 6, 1318-1319.	30.7	7
367	Tumor suppressor p53 regulation and function. Frontiers in Bioscience - Landmark, 2000, 5, d424-437.	3.0	4
368	Repression of BRCA1 through a Feedback Loop Involving p53. Journal of Biological Chemistry, 2000, 275, 31869-31875.	3.4	59
369	BRCA1 Effects on the Cell Cycle and the DNA Damage Response Are Linked to Altered Gene Expression. Journal of Biological Chemistry, 2000, 275, 2777-2785.	3.4	193
370	p21WAF1/CIP1 Inhibits Initiator Caspase Cleavage by TRAIL Death Receptor DR4. Biochemical and Biophysical Research Communications, 2000, 269, 179-190.	2.1	93
371	The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis. Molecular Therapy, 2000, 1, 130-144.	8.2	111
372	Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene, 1999, 18, 2357-2365.	5.9	110
373	The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene, 1999, 18, 4153-4159.	5.9	156
374	Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene, 1999, 18, 6411-6418.	5.9	98
375	BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene, 1999, 18, 6605-6614.	5.9	68
376	The p53 pathway and apoptosis. Journal of Cellular Physiology, 1999, 181, 231-239.	4.1	187
377	The TRAIL to an anti-cancer agent. Drug Resistance Updates, 1999, 2, 79-80.	14.4	5
378	Transcriptional Activation of the Cyclin-Dependent Kinase Inhibitor p21 by PML/RARÎ±. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 1999, 1, 125-131.	1.6	5

#	Article	IF	Citations
379	Comparative Gene Expression Profiling in Response to p53 in a Human Lung Cancer Cell Line. Biochemical and Biophysical Research Communications, 1999, 264, 891-895.	2.1	6
380	Induction of p21^{WAF1/CIP1} and Inhibition of Cdk2 Mediated by the Tumor Suppressor p16^{INK4a}. Molecular and Cellular Biology, 1999, 19, 3916-3928.	2.3	125
381	The Role of p53 in Chemosensitivity. , 1999, , 37-52.		0
382	Regulation ofp53downstream genes. Seminars in Cancer Biology, 1998, 8, 345-357.	9.6	756
383	Potential role for Cathepsinâ€‰D in p53-dependent tumor suppression and chemosensitivity. Oncogene, 1998, 16, 2177-2183.	5.9	202
384	BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene, 1998, 16, 1713-1721.	5.9	421
385	Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. , 1998, 75, 933-940.		60
386	Tumor suppressor gene therapy for cancer: from the bench to the clinic. Drug Resistance Updates, 1998, 1, 205-210.	14.4	4
387	Identification of a Novel AP-2 Consensus DNA Binding Site. Biochemical and Biophysical Research Communications, 1998, 243, 307-316.	2.1	16
388	FADD: Essential for Embryo Development and Signaling from Some, But Not All, Inducers of Apoptosis. Science, 1998, 279, 1954-1958.	12.6	852
389	The Gfi-1B Proto-Oncoprotein Represses p21^{WAF1} and Inhibits Myeloid Cell Differentiation. Molecular and Cellular Biology, 1998, 18, 2462-2473.	2.3	107
390	Role of oncogenes in resistance and killing by cancer therapeutic agents. Current Opinion in Oncology, 1997, 9, 79-87.	2.4	141
391	Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionSelfcloseTable. Oncogene, 1997, 14, 1047-1057.	5.9	174
392	AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genetics, 1997, 15, 78-82.	21.4	277
393	KILLER/DR5 is a DNA damageâ€“inducible p53â€“regulated death receptor gene. Nature Genetics, 1997, 17, 141-143.	21.4	1,005
394	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl. Nature, 1997, 389, 187-190.	27.8	509
395	p21 (WAF1/CIP1) Expression Is Induced in Newly Nondividing Cells in Diverse Epithelia and during Differentiation of the Caco-2 Intestinal Cell Line. Experimental Cell Research, 1996, 227, 171-181.	2.6	124
396	Proteasome-Dependent Regulation of p21WAF1/CIP1Expression. Biochemical and Biophysical Research Communications, 1996, 227, 564-569.	2.1	227

#	Article	IF	Citations
397	The WAF 1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients. Human Pathology, 1996, 27, 324-329.	2.0	10
398	In vitro evaluation of ap53-expressing adenovirus as an anti-cancer drug. International Journal of Cancer, 1996, 67, 386-392.	5.1	188
399	p53 and chemosensitivity. Nature Medicine, 1996, 2, 255-256.	30.7	75
400	In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. , 1996, 67, 386.		1
401	Polymerase Î˝ variants in RER colorectal tumours. Nature Genetics, 1995, 9, 10-11.	21.4	129
402	Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Research, 1992, 20, 2287-2291.	14.5	240
403	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 1992, 71, 587-597.	28.9	3,006
404	Definition of a consensus binding site for p53. Nature Genetics, 1992, 1, 45-49.	21.4	1,944
405	Mechanisms of error discrimination by Escherichia coli DNA polymerase I. Biochemistry, 1988, 27, 546-553.	2.5	35
406	Stability of acetylated and superguanidinated chymotrypsinogens. Archives of Biochemistry and Biophysics, 1982, 216, 600-604.	3.0	11
407	The p53 pathway and apoptosis. , 0, .		1